In cancer biology, aberrant activation of MERTK by PROS1 contributes to tumor progression by promoting cell survival, proliferation, migration, and immune evasion, and has been implicated in a variety of solid tumors, including lung, breast, and glioblastoma multiforme, where its overexpression correlates with poor prognosis and resistance to apoptosis [14–17]. Here, PROS1 is linked to cancer.